IDEXX Laboratories Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately in reliance on SEC Release No. 34-39538.
IDEXX Laboratories announced that Executive Vice President, Global Strategy and Commercial, Nimrata Hunt, PhD, will leave her role effective April 13, 2026, then serve as a special advisor on an as‑needed basis until July 13, 2026.
Under a separation agreement, IDEXX will provide salary continuation for 104 weeks totaling $1,230,000 and pay her target annual bonus for two years totaling $984,000, alongside a $50,000 COBRA-related lump sum, $10,000 in transition assistance and up to $6,000 per year for 2025 and 2026 tax or financial planning services.
Unvested stock options, restricted stock units and performance stock units will be forfeited as of the final employment date, while vested stock options remain exercisable under existing award terms. IDEXX characterizes the move as a termination without cause tied to elimination of her position and obtained a broad release, non‑disparagement and ongoing cooperation commitments.
IDEXX Laboratories, Inc. presents its preliminary 2026 Proxy Statement summarizing 2025 performance, corporate priorities and governance matters.
The company reports $4.3B revenue, $13.08 diluted EPS, 10% reported revenue growth and highlights innovation milestones and a planned CEO transition effective upon adjournment of the 2026 Annual Meeting on May 12, 2026.
IDEXX Laboratories executive Sharon E. Underberg, EVP, GC & Corporate Secretary, exercised an incentive stock option on March 3, 2026. The option conversion resulted in 197 shares of common stock at a transaction price of 505.5300 per share, bringing her direct common stock holdings to 7,137.654 shares.
The incentive stock option right-to-buy covered 197 shares and, following the exercise, showed 0 derivative shares remaining. A footnote states the option grant to buy issuer common stock vested on February 14, 2026, indicating this was a scheduled equity award exercise.
IDEXX Laboratories Executive Vice President Nimrata Hunt sold 1,758 shares of common stock in an open-market transaction on March 3, 2026 at a weighted average price of $634.5718 per share. After this sale, Hunt directly held 18,140.944 shares and indirectly held 160 shares jointly with a spouse.
According to a footnote, the weighted average sale price reflects individual trades executed between $634.5301 and $634.8201 per share.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported corrected equity awards and updated holdings. The amended filing states that on February 12, 2026 he received a non‑qualified stock option for 13,667 shares and an incentive stock option for 162 shares, both with an exercise price equal to that day’s closing stock price.
The non‑qualified option vests in four annual installments beginning February 14, 2027, while the incentive stock option becomes exercisable in a single installment on February 14, 2030. The amendment clarifies that previously reported grants of 6,319 restricted stock units did not occur, and notes his common stock holdings include 184 vested but deferred restricted stock units.
IDEXX Laboratories reported a proposed sale of 1,758 common shares via Form 144, listed with Morgan Stanley Smith Barney LLC as the broker on 03/03/2026.
The shares are labeled as exercised shares with an exercise date of 08/06/2025. The excerpt also shows prior sales of 2,693 common shares on 02/25/2026 with an aggregate dollar amount of 1,781,530.72.
IDEXX Laboratories President and CEO Jonathan Jay Mazelsky exercised stock options for 23,523 shares of common stock at exercise prices of $141.6000 and $505.5300. He then sold 23,326 shares in multiple open-market trades at prices including $650.6695 and $663.0439, ending with 83,803.302 shares held directly.
IDEXX Laboratories Executive Vice President Nimrata Hunt reported an open-market sale of common stock. On February 26, 2026, Hunt sold 2,693 shares at a weighted average price of $661.5413 per share in open-market transactions. After the sale, Hunt directly owned 19,898.944 common shares and indirectly owned 160 shares jointly with a spouse. A footnote explains that the sale prices ranged from $661.35 to $661.8275 per share, with detailed trade breakdowns available upon request.